Yucheng Lu | Neuroscience | Research Excellence Award

Prof. Yucheng Lu | Neuroscience | Research Excellence Award

Linyi People's Hospital | China

Prof. Yucheng Lu is a distinguished researcher whose scholarly contributions span cancer biology, immunology, and translational biomedical sciences. With 352 citations, 26 indexed publications, and an h-index of 13, he has established a strong research footprint in molecular oncology and disease pathology. Over his academic career, he has published 40 peer-reviewed papers, including 25 as first or corresponding author, reflecting consistent leadership in scientific inquiry. His work encompasses cutting-edge topics such as tumor-associated macrophage regulation in glioma, prognostic biomarkers in low-grade glioma, colorectal cancer therapeutics, and single-cell transcriptomics in esophageal cancer. In addition, he has explored metabolic and immunological disease interactions, cancer proliferation mechanisms, and neural electrophysiological responses. As a principal investigator, he has led 7 provincial and municipal research projects and contributed to 8 national and ministerial-level initiatives, demonstrating strong project management and interdisciplinary collaboration. His research excellence has earned 3 Science and Technology Achievement Awards, alongside innovations represented by 1 invention patent and 6 software copyrights. Through these achievements, Prof. Lu continues to advance biomedical research with significant scientific, clinical, and technological impact.

Profile : Scopus | Orcid

Featured Publications

Shi, H., Cheng, Y., Chao, D., Song, Q., Han, L., Li, H., Lu, Y., & Wang, M. (2025). Spatiotemporal profiling of endocytic regulators in the immunosuppressive TAM microenvironment of glioma. Brain Research, 150086. (In press)

Author names not provided. (2025). Identification of CDKN3 overexpression as a marker of poor prognosis and potential therapeutic target in low-grade glioma. Scientific Reports.

Author names not provided. (2025). Okanin suppresses the growth of colorectal cancer cells by targeting Peroxiredoxin 5. Advanced Science.

Shi, K., Li, Y., Yang, L., Zhang, Z., Guo, D., Zhang, J., & Lu, Y. (2022). Profiling transcriptional heterogeneity of epithelium, fibroblasts, and immune cells in esophageal squamous cell carcinoma by single-cell RNA sequencing. The FASEB Journal, 0892-6638.

Zhao, J. Z., Lu, Y. C., Wang, Y. M., Xiao, B. L., Li, H. Y., Lee, S. C., & Wang, L. J. (2022). Association between diabetes and acute lymphocytic leukemia, acute myeloid leukemia, non-Hodgkin lymphoma, and multiple myeloma. International Journal of Diabetes in Developing Countries, 0973-3930.

Shi, K., Zhang, J. Z., Yang, L., Li, N. N., Yue, Y., Du, X. H., Zhang, X. Z., Lu, Y. C., & Guo, D. (2021). Protein deubiquitylase USP3 stabilizes Aurora A to promote proliferation and metastasis of esophageal squamous cell carcinoma. BMC Cancer, 1471-2407.

Lu, Y., Lv, B., & Song, Q. (2019). Transcranial electrical stimulation motor-evoked potentials in a spinal cord ischaemia rabbit model. Chinese Neurosurgical Journal, 2057-4967.

Lu, Y. C., Wang, P., Wang, J., Ma, R., & Lee, S. C. (2019). PCNA and JNK1-Stat3 pathways respectively promote and inhibit diabetes-associated centrosome amplification by targeting the ROCK1/14-3-3σ complex in human colon cancer HCT116 cells. Journal of Cellular Physiology.

Jeong A Kim | Medicine and Dentistry | Best Researcher Award

Prof. Jeong A Kim | Medicine and Dentistry | Best Researcher Award

St. Vincent Hospital, The Catholic University of Korea | South Korea

Author Profile

Scopus

Early Academic Pursuits ✨

Prof. Jeong A Kim embarked on an illustrious academic journey in the field of medicine, laying a solid foundation at the Catholic University Medical College. She completed her premedical course in 1986, followed by earning her Doctor of Medicine degree in 1990. Her passion for internal medicine and hematology led her to pursue advanced studies at The Catholic University of Korea, where she obtained a Master’s degree in 1998 and a Ph.D. in 2001. This strong academic background established her as a dedicated scholar committed to the advancement of medical sciences.

Professional Endeavors 🏥

Prof. Kim's professional career began with rigorous postdoctoral training. She completed her internship at St. Mary’s Hospital in 1991, followed by a residency in Internal Medicine at Catholic University Medical College until 1995. She further honed her expertise in hemato-oncology through a fellowship at Samsung Medical Center. Her international exposure expanded when she joined the Department of Microbiology and Immunology at IUPUI, USA, as a postdoctoral researcher. Her academic appointments at The Catholic University of Korea saw a steady rise, from Instructor in 1997 to Assistant Professor in 2001, Associate Professor in 2009, and finally attaining the prestigious title of Professor of Internal Medicine in 2014. In parallel, she has been a dedicated physician at St. Vincent Hospital since 1997 and has been leading the hematology and stem cell transplantation center since 2018.

Contributions and Research Focus 📝

Prof. Kim has made groundbreaking contributions in hematology and oncology, with a primary focus on stem cell transplantation, multiple myeloma, and lymphoma. Her extensive clinical trials and research studies have played a pivotal role in developing new treatment modalities for hematologic malignancies. Her work in targeted therapies, chemotherapy combinations, and immunotherapy has significantly improved patient outcomes and quality of life. She has been involved in more than 60 clinical trials, evaluating novel drug efficacy and safety, including studies on Zoledronic acid for multiple myeloma, targeted treatments like Dasatinib for leukemia, and the role of rituximab in lymphoma. Her research has also delved into prognostic factors, precision medicine, and innovative therapeutic strategies for refractory and relapsed hematologic diseases.

Accolades and Recognition 🏆

Prof. Kim's relentless pursuit of excellence has earned her recognition from esteemed medical institutions and societies. As a member of the Korean Association of Internal Medicine, the Korean Hematology Association, and the American Hematology Association, she has played an instrumental role in shaping global hematologic research. Her contributions have been acknowledged through numerous awards, invitations as a keynote speaker, and influential publications in high-impact medical journals.

Impact and Influence ✨

With a career spanning decades, Prof. Kim has mentored numerous young medical professionals, guiding them in clinical research and evidence-based medical practice. Her work has directly influenced hematologic treatment protocols in Korea and internationally. Her leadership in hematology and stem cell transplantation has set new benchmarks in patient care and innovative treatment approaches.

Legacy and Future Contributions 🌟

Prof. Jeong A Kim's legacy is deeply ingrained in the advancements of hematology and oncology. Her dedication to research, patient care, and education continues to inspire the next generation of medical professionals. Looking ahead, she remains committed to pioneering more targeted therapies, enhancing stem cell transplantation techniques, and improving long-term survival rates for hematologic malignancy patients. With ongoing research and collaborations, she is poised to make even greater strides in the field, leaving an indelible mark on medical science and patient care.

 

Publications


📄 The presence of clonal isotype switch after autologous stem cell transplantation as a prognostic biomarker for long-term survival in patients with multiple myeloma
Authors: H. Cho, J. Kim, Y. Park, Y. Kim, J. Kim, Jeong-ah
Journal: Leukemia Research
Year: 2025


📄 Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
Authors: N.L. Bartlett, U.H. Hahn, W. Kim, F. Jie, J. Kim, Jeong-ah
Journal: Journal of Clinical Oncology
Year: 2025


📄 Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trials
Authors: D. Shin, S. Park, E. Jang, W. Lee, D. Kim
Journal: Leukemia Research
Year: 2024


📄 Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study
Authors: H.Y. Yhim, Y. Park, J. Kim, Jeong-ah, D. Yang, J. Kwak
Journal: The Korean Journal of Internal Medicine
Year: 2024


Dong Hyun Kim | Medicine and Dentistry | Young Scientist Award

Dr. Dong Hyun Kim | Medicine and Dentistry | Young Scientist Award

Seoul National University College of Medicine | South Korea

Author Profile

Scopus

Orcid

Early Academic Pursuits 🎓

Dr. Dong Hyun Kim embarked on his medical journey at the prestigious Seoul National University College of Medicine, earning his Bachelor of Medicine in 2019. His academic rigor continued with a Master's degree in Medical Science, specializing in Translational Medicine, which he completed in 2024. His academic training laid the foundation for his future endeavors in clinical oncology and hematologic malignancies, blending medicine with cutting-edge research.

Professional Endeavors 🏥

Dr. Kim's professional career began at Seoul National University Hospital, where he completed his internship and then advanced to a Resident Doctor position in the Department of Internal Medicine. His expertise expanded into the field of Hemato-Oncology, where he currently serves as an External Clinical Researcher. His clinical work, especially in the realm of cancer treatment and translational medicine, has contributed significantly to patient care and scientific discovery.

Contributions and Research Focus 🔬

Dr. Kim’s research has made a considerable impact on hematologic malignancies and the use of artificial intelligence in oncology. His work spans various domains, including allogeneic stem cell transplantation, tumor-infiltrating lymphocytes as biomarkers, and predictive modeling in cancer treatment. Through his numerous publications, he has explored innovative treatments and personalized medicine, particularly focusing on improving patient outcomes in myelofibrosis, thymic epithelial neoplasms, and head and neck squamous cell carcinoma.

Accolades and Recognition 🏅

Dr. Kim has received numerous awards that underscore his contributions to the field. He earned the Best Oral Presentation Award at ICBMT 2022, a Presidential Oral Presentation at JSMO 2024, and another Best Oral Presentation Award at ICKSH 2024. These recognitions reflect his leadership in oncology research and his ability to present complex ideas with clarity and authority.

Impact and Influence 🌍

Through his published works, Dr. Kim has influenced the global oncology community. His research on artificial intelligence in oncology, predictive biomarkers, and innovative therapeutic approaches has opened new pathways in cancer treatment. His contributions, especially in improving treatment strategies for hematologic malignancies and solid tumors, are helping shape the future of personalized medicine.

Legacy and Future Contributions 🌟

Dr. Kim is poised to continue influencing the fields of clinical oncology and translational medicine. His dedication to research, combined with his clinical expertise, ensures that he will remain a key figure in advancing cancer treatment and improving patient outcomes. His future endeavors, backed by a solid academic and professional foundation, are expected to further elevate the standards of oncological care and research.

Publications


📄 Dual T-cell depletion with individually tailored anti-thymocyte globulin and attenuated dose of post-transplant cyclophosphamide in haploidentical peripheral stem cell transplantation
Author: Kim, D.H., Shin, D.-Y., Koh, Y., Byun, J.M., Hong, J.
Journal: Scientific Reports
Year: 2024


📄 Effects of tertiary palliative care on the pattern of end-of-life care in patients with hematologic malignancies in Korea
Author: Kim, D.H., Youk, J., Byun, J.M., Yoo, S.H., Shin, D.-Y.
Journal: European Journal of Haematology
Year: 2024


📄 Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study
Author: Kim, D.H., Lim, S.T., Kim, H.R., Shin, S.-H., Yun, H.J.
Journal: Oral Oncology
Year: 2024


📄 Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a predictive biomarker for axitinib in adenoid cystic carcinoma
Author: Kim, D.H., Lim, Y., Ock, C.-Y., Kim, S.-B., Keam, B.
Journal: Head and Neck
Year: 2023


 

Filippo Carannante | Medicine and Dentistry | Best Research Award

Dr. Filippo Carannante | Medicine and Dentistry | Best Research Award 

UOC Chirurgia Colorettale, Fondazione Policlinico Campus Bio-Medico di Roma | Italy 

Author Profile

Scopus

Orcid

🎓 Early Academic Pursuits

Dr. Filippo Carannante's academic journey began at the Bio-Medico Campus University of Rome, where he graduated with a degree in Medicine and Surgery, achieving a perfect score of 110/110 cum laude. He completed a specialized training program in General Surgery Residency at the same institution, culminating in a thesis on the oncological outcomes of rectal cancer patients. He further enhanced his expertise with various fellowships and specialized courses, including a PhD program in Biomedical Sciences and Bioethics focused on osteo-oncological diseases.

💼 Professional Endeavors

Dr. Carannante has held several prestigious positions in the field of colorectal and oncological surgery. Since November 2021, he has been a consultant colorectal surgeon at the Campus Bio-Medico Polyclinic Foundation of Rome. In September 2023, he was appointed a professor of Oncological and Digestive Surgery at the Campus Bio-Medico University of Rome. He is also an active member of the Italian Society of Colorectal Surgery (SICCR) and the Italian Society of Surgical Oncology (SICO), where he serves on the young boards, and is part of the Lower GI Group at the American College of Surgeons (ACS).

🔬 Contributions and Research Focus

Dr. Carannante's research contributions are significant, particularly in the areas of colorectal surgery and minimally invasive surgical techniques. His work includes innovative studies on the outcomes of rectal cancer treatments and the feasibility of minimally invasive colectomy in fragile patients. He has also contributed to advancements in laparoscopic and abdominal wall surgery, and has been involved in multiple research projects at renowned institutions across Europe.

🏆 Accolades and Recognition

Dr. Carannante has received numerous awards for his contributions to surgery and research. Notably, he was awarded the "Ettore Ruggieri" Scholarship by the Italian Society of Surgery (SIC) in 2023 and the "Francesco Mazzeo" Award by the Italian Society of Pathology of the Digestive System (SIPAD) in 2024. Additionally, he received the "Best Oral Presentation" award at a national congress for his study on minimally invasive colectomy.

🌍 Impact and Influence

Dr. Carannante's influence extends beyond his immediate professional environment. He serves on the editorial boards of several prestigious journals, including the International Journal of Colorectal Disease and the World Journal of Surgical Oncology. His h-index of 15 and over 828 citations highlight the impact of his research on the global medical community. He is also a reviewer for numerous scientific publications, ensuring the quality and advancement of research in his field.

🏅 Legacy and Future Contributions

Dr. Carannante's legacy is marked by his dedication to advancing the field of colorectal and oncological surgery through both clinical practice and research. His ongoing roles in various surgical societies and academic institutions position him to continue making significant contributions to the medical field. His commitment to education, research, and clinical excellence ensures that his influence will be felt for years to come, inspiring future generations of surgeons and researchers.

 

Publications 📄


📄Evaluation of Short-Term Effects on Colorectal Surgery Elective Patients after Implementing a Patient Blood Management Program: A Multicenter Retrospective Analysis
Authors: Filippo Carannante, Gabriella Teresa Capolupo, Manuel Barberio, Amedeo Altamura, Valentina Miacci, Martina Zenobia Scopigno, Erika Circhetta, Gianluca Costa, Marco Caricato, Massimo Giuseppe Viola
Journal: [Special Issue: Challenges in Minimally Invasive Colorectal and Abdominal Wall Surgery], Year : 2024


📄Laparoscopic right hemicolectomy: a SICE (Società Italiana di Chirurgia Endoscopica e Nuove Tecnologie) network prospective study on the approach to right colon lymphadenectomy in Italy: is there a standard?—CoDIG 2 (ColonDx Italian Group)
Authors: Anania, G., Chiozza, M., Campagnaro, A., Zago, M., Zerbinati, A.
Journal: Surgical Endoscopy, Year : 2024


📄Effect of centre volume on pathological outcomes and postoperative complications after surgery for colorectal cancer: results of a multicentre national study
Authors: Rottoli, M., Spinelli, A., Pellino, G., Rausa, E., Celentano, V.
Journal: British Journal of Surgery, Year : 2024


📄Long-term patient-reported outcomes after anti-reflux surgery for gastroesophageal reflux disease and hiatal hernia repair: a single-center experience
Authors: Peltrini, R., Carannante, F., Giovine, G., Capolupo, G.T., Borzomati, D.
Journal: Minerva Surgery, Year : 2023


📄Surgeons’ practice and preferences for the anal fissure treatment: results from an international survey
Authors: Balla, A., Saraceno, F., Shalaby, M., Ziprin, P., Zizzo, M.
Journal: Updates in Surgery, Year : 2023